We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

MAST GROUP

Mast Group is an independent manufacturer and supplier of diagnostic products for clinical, industrial and veterinary... read more Featured Products: More products

Download Mobile App





Mast Group Introduces New MAST CARBA PAcE for Rapid Carbapenemase Detection

By LabMedica International staff writers
Posted on 21 Nov 2019
Print article
Image: MAST® CARBA PAcE (Photo courtesy of Mast Group Ltd.)
Image: MAST® CARBA PAcE (Photo courtesy of Mast Group Ltd.)
Mast Group Ltd. (Liverpool, UK) was amongst the 4,500 exhibitors from 70 countries that presented their products and services at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies. At the 2019 edition of MEDICA, Mast introduced the new MAST CARBA PAcE for rapid carbapenemase detection in Pseudomonas spp., Acinetobacter spp. and Enterobacterales.

The company’s MAST ASSURE and CRYOBANK range also featured on the booth this year alongside its extensive range of MASTDISCS for antimicrobial susceptibility and resistance marker testing. MAST ASSURE’s extensive range contains both polyvalent and monovalent diagnostic antisera for the identification of Salmonella spp according to the expression of somatic antigens. Bacterial serotype can be determined by both slide agglutination and test tube agglutination methods.

The company’s MASTDISCS AST is available as an extensive range of antibiotic susceptibility test discs. Mast also offers an extensive range of MASTDISCS Combi antibiotic resistance detection sets for identification and differentiation of enzyme types using a combination disc technology, incorporating specific inhibitors to accurately detect extended spectrum ß-lactamase (ESßL), AmpC cephalosporinase, Metallo ß-lactamase (MBL) including VIM, IMP and NDM Klebsiella pneumoniae carbapenemase (KPC) and OXA-48 like carbapenemases.

Related Links:
Mast Group Ltd.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: AI analysis of DNA fragmentomes and protein biomarkers noninvasively detects ovarian cancer (Photo courtesy of Adobe Stock)

Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer

Ovarian cancer is one of the most common causes of cancer deaths among women and has a five-year survival rate of around 50%. The disease is particularly lethal because it often doesn't cause symptoms... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Pathology

view channel
Image: ‘Virtual biopsy’ allows clinicians to analyze skin noninvasively (Photo courtesy of Stanford Medicine)

Virtual Skin Biopsy Determines Presence of Cancerous Cells

When dermatologists spot an unusual mark on a patient's skin, they face a choice: monitor it for some time or remove it for biopsy. Similarly, when removing breast tumors, surgeons must send excised tissues... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.